Table 4.
Incidence of TEAEs of interest by time to new onset for ibrutinib+BR-treated patients
| TEAE, n (%) | 0–1 year (n = 287) | 1–2 years (n = 216) | 2–3 years (n = 188) | > 3 years (n = 83) |
|---|---|---|---|---|
| Infection | 190 (66.2) | 22 (10.2) | 4 (2.1) | 1 (1.2) |
| Neutropenia | 164 (57.1) | 3 (1.4) | 0 | 0 |
| Nausea | 105 (36.6) | 1 (0.5) | 0 | 0 |
| Diarrhea | 98 (34.1) | 9 (4.2) | 1 (0.5) | 2 (2.4) |
| Thrombocytopenia | 86 (30.0) | 2 (0.9) | 1 (0.5) | 0 |
| Bleeding | 84 (29.3) | 10 (4.6) | 4 (2.1) | 1 (1.2) |
| Pyrexia | 69 (24.0) | 5 (2.3) | 4 (2.1) | 0 |
| Anemia | 64 (22.3) | 2 (0.9) | 2 (1.1) | 0 |
| Fatigue | 58 (20.2) | 5 (2.3) | 3 (1.6) | 1 (1.2) |
| Cough | 48 (16.7) | 12 (5.6) | 4 (2.1) | 1 (1.2) |
| Pneumonia | 38 (13.2) | 15 (6.9) | 7 (3.7) | 1 (1.2) |
| Upper respiratory tract infection | 38 (13.2) | 17 (7.9) | 4 (2.1) | 2 (2.4) |
| Hypertension | 27 (9.4) | 8 (3.7) | 4 (2.1) | 0 |
| Atrial fibrillation/flutter | 19 (6.6) | 4 (1.9) | 6 (3.2) | 0 |
TEAE treatment-emergent adverse event